BioCentury | Aug 3, 2020
Product Development

Data Bytes: tallying COVID-19 development programs

...a May Cell publication . XVR-011 has improved viral neutralization and target binding affinity (see “VIB...
BioCentury | Aug 1, 2020
Emerging Company Profile

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

...Nearly 20 years since the launch of Ablynx, VIB has spun out its fourth company with...
...investigators at VIB and Professors at Ghent University. The company has filed patent applications through VIB...
...Founded: 2020 by Flanders Institute for Biotechnology (VIB), UCB Ventures and Fund+ University collaborators: VIB-UGent, VIB...
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

...He was SVP and chief information officer of Teradata Corp. Belgium-based life sciences research institute VIB...
...co-managing director and head of Innovation & Business. He was head of business development of VIB’s...
BioCentury | Mar 16, 2020
Product Development

COVID-19 Roundup: Trial starts for Moderna, Sanofi-Regeneron and BioNTech; plus Thermo Fisher, Roche and VIB

...and cobas 8800 systems. VIB reveals progress with new anti-COVID-19 mechanism Flanders Institute of Biotechnology (VIB...
...the virus in early preclinical work. VIB said the group, led by Xavier Saelens at VIB...
...AG Moderna Inc. Sanofi Regeneron Pharmaceuticals Inc. Thermo Fisher Scientific Inc. Shanghai Fosun Pharmaceutical Group Co. Ltd. Flanders Institute for Biotechnology (VIB) mRNA-1273 BNT162 COVID-19 cov19count cov19count...
BioCentury | Mar 6, 2020
Deals

Cancer-focused Orionis debuts with small molecule discovery deal with Novartis

...CTO Jan Tavernier, who is a professor at VIB-Ghent University, along with Belgian research institute VIB...
BioCentury | Feb 22, 2020
Product Development

COVID-19 mAb menagerie

...to include therapies to treat COVID-19. A Belgian team led by Flanders Institute for Biotechnology (VIB...
...domain that’s conserved between SARS-CoV and SARS-CoV-2. Tim Van Acker, who is BD manager at VIB...
...Biologics Inc. National Institutes of Health Regeneron Pharmaceuticals Inc. BARDA Ghent University WuXi Biologics Inc. Ligand Pharmaceuticals Inc. Flanders Institute for Biotechnology (VIB) COVID19 coronavirus cov19sci cov19count cov19count cov19sci...
BioCentury | Feb 21, 2020
Emerging Company Profile

Montis: Exploring an untouched macrophage subset in immuno-oncology

...Ventures in as many weeks. Droia, which teamed up with the Flanders Institute for Biotechnology (VIB...
...destroyed to treat solid tumors. Instead, Montis’ scientific founders Peter Carmeliet and Massimiliano Mazzone at VIB-KU...
...Clinical status: Preclinical Founded: 2019 by Droia Ventures; KU Leuven; VIB University collaborators: KU Leuven; VIB...
BioCentury | Feb 8, 2020
Product Development

Feb. 7 Product Development Quick Takes: Myriad tumbles on revenue miss; plus Verana, Sanofi, VIB, Coda, Blueprint

...Inc. New antibody against 2019-nCoV from VIB-UGent, NIH, UT Austin A collaboration between researchers at VIB-UGent...
...human receptor for viral binding. ACE2 is the cognate receptor of the SARS-CoV S protein. VIB...
...Angiotensin-converting enzyme 2 (ACE2) BTK - Bruton’s tyrosine kinase BioCentury Staff PRN2246, SAR442168 Flanders Institute for Biotechnology (VIB) Ghent...
BioCentury | Oct 9, 2019
Company News

With Japan submission nearing in NMOSD, Viela picks Mitsubishi as territorial partner

Just days after completing its IPO, Viela will receive another cash infusion from a partnership giving Mitsubishi Tanabe territorial rights to lead program inebilizumab to treat neuromyelitis optical spectrum disorder. Viela Bio Inc. (NASDAQ:VIE) will...
BioCentury | Aug 29, 2019
Financial News

MedImmune-spinout Viela seeking $150M IPO

Autoimmune disease company Viela proposed Thursday to raise up to $150 million in an IPO -- two days after FDA accepted its first BLA for review, and two months after it closed a $75 million...
Items per page:
1 - 10 of 114
BioCentury | Aug 3, 2020
Product Development

Data Bytes: tallying COVID-19 development programs

...a May Cell publication . XVR-011 has improved viral neutralization and target binding affinity (see “VIB...
BioCentury | Aug 1, 2020
Emerging Company Profile

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

...Nearly 20 years since the launch of Ablynx, VIB has spun out its fourth company with...
...investigators at VIB and Professors at Ghent University. The company has filed patent applications through VIB...
...Founded: 2020 by Flanders Institute for Biotechnology (VIB), UCB Ventures and Fund+ University collaborators: VIB-UGent, VIB...
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

...He was SVP and chief information officer of Teradata Corp. Belgium-based life sciences research institute VIB...
...co-managing director and head of Innovation & Business. He was head of business development of VIB’s...
BioCentury | Mar 16, 2020
Product Development

COVID-19 Roundup: Trial starts for Moderna, Sanofi-Regeneron and BioNTech; plus Thermo Fisher, Roche and VIB

...and cobas 8800 systems. VIB reveals progress with new anti-COVID-19 mechanism Flanders Institute of Biotechnology (VIB...
...the virus in early preclinical work. VIB said the group, led by Xavier Saelens at VIB...
...AG Moderna Inc. Sanofi Regeneron Pharmaceuticals Inc. Thermo Fisher Scientific Inc. Shanghai Fosun Pharmaceutical Group Co. Ltd. Flanders Institute for Biotechnology (VIB) mRNA-1273 BNT162 COVID-19 cov19count cov19count...
BioCentury | Mar 6, 2020
Deals

Cancer-focused Orionis debuts with small molecule discovery deal with Novartis

...CTO Jan Tavernier, who is a professor at VIB-Ghent University, along with Belgian research institute VIB...
BioCentury | Feb 22, 2020
Product Development

COVID-19 mAb menagerie

...to include therapies to treat COVID-19. A Belgian team led by Flanders Institute for Biotechnology (VIB...
...domain that’s conserved between SARS-CoV and SARS-CoV-2. Tim Van Acker, who is BD manager at VIB...
...Biologics Inc. National Institutes of Health Regeneron Pharmaceuticals Inc. BARDA Ghent University WuXi Biologics Inc. Ligand Pharmaceuticals Inc. Flanders Institute for Biotechnology (VIB) COVID19 coronavirus cov19sci cov19count cov19count cov19sci...
BioCentury | Feb 21, 2020
Emerging Company Profile

Montis: Exploring an untouched macrophage subset in immuno-oncology

...Ventures in as many weeks. Droia, which teamed up with the Flanders Institute for Biotechnology (VIB...
...destroyed to treat solid tumors. Instead, Montis’ scientific founders Peter Carmeliet and Massimiliano Mazzone at VIB-KU...
...Clinical status: Preclinical Founded: 2019 by Droia Ventures; KU Leuven; VIB University collaborators: KU Leuven; VIB...
BioCentury | Feb 8, 2020
Product Development

Feb. 7 Product Development Quick Takes: Myriad tumbles on revenue miss; plus Verana, Sanofi, VIB, Coda, Blueprint

...Inc. New antibody against 2019-nCoV from VIB-UGent, NIH, UT Austin A collaboration between researchers at VIB-UGent...
...human receptor for viral binding. ACE2 is the cognate receptor of the SARS-CoV S protein. VIB...
...Angiotensin-converting enzyme 2 (ACE2) BTK - Bruton’s tyrosine kinase BioCentury Staff PRN2246, SAR442168 Flanders Institute for Biotechnology (VIB) Ghent...
BioCentury | Oct 9, 2019
Company News

With Japan submission nearing in NMOSD, Viela picks Mitsubishi as territorial partner

Just days after completing its IPO, Viela will receive another cash infusion from a partnership giving Mitsubishi Tanabe territorial rights to lead program inebilizumab to treat neuromyelitis optical spectrum disorder. Viela Bio Inc. (NASDAQ:VIE) will...
BioCentury | Aug 29, 2019
Financial News

MedImmune-spinout Viela seeking $150M IPO

Autoimmune disease company Viela proposed Thursday to raise up to $150 million in an IPO -- two days after FDA accepted its first BLA for review, and two months after it closed a $75 million...
Items per page:
1 - 10 of 114